西洛他唑在间歇性跛行实用治疗方案中的疗效。
Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication.
作者信息
Lee Constance, Nelson Peter R
机构信息
Department of Surgery, University of Florida College of Medicine and Malcom Randall VA Medical Center, Gainesville, FL, USA.
出版信息
Vasc Endovascular Surg. 2014 Apr;48(3):224-9. doi: 10.1177/1538574413518121. Epub 2014 Jan 6.
BACKGROUND
Controlled trials of cilostazol for claudication demonstrate improvements in walking distance and quality of life. Without the structure of a study environment, it is not certain that cilostazol has similar efficacy.
METHOD
Retrospective review of patients prescribed cilostazol for claudication was undertaken. Patients were advised to stop smoking and increase exercise but no formal programs were instituted. The primary outcome measure was patient-reported improvement in claudication symptoms. Secondary outcomes were smoking cessation and participation in regular exercise.
RESULTS
Over a 2-year period, 77 patients were prescribed cilostazol as initial treatment for claudication. Follow-up for 3 months was available for 69 (90%) patients. Noncompliance was reported in 20% of patients. Of the overall group, 58% (73% of compliant patients) of patients reported improvement in claudication symptoms, 4% of patients reported smoking cessation, and 7% reported regular exercise.
CONCLUSION
Despite minimal behavior modification, up to 70% of patients taking cilostazol report an improvement in claudication symptoms with few side effects.
背景
西洛他唑治疗间歇性跛行的对照试验表明，患者的行走距离和生活质量有所改善。在缺乏研究环境结构的情况下，尚不确定西洛他唑是否具有类似疗效。
方法
对因间歇性跛行而开具西洛他唑处方的患者进行回顾性研究。建议患者戒烟并增加运动量，但未制定正式计划。主要结局指标是患者报告的间歇性跛行症状改善情况。次要结局是戒烟和定期锻炼。
结果
在两年时间里，77例患者被开具西洛他唑作为间歇性跛行的初始治疗药物。69例（90%）患者获得了3个月的随访数据。20%的患者报告存在不依从情况。在整个研究组中，58%（依从患者中的73%）的患者报告间歇性跛行症状有所改善，4%的患者报告已戒烟，7%的患者报告进行了定期锻炼。
结论
尽管行为改变很少，但高达70%服用西洛他唑的患者报告间歇性跛行症状有所改善，且副作用很少。
Zotero 插件